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Abstract
Background: Inherited retinal disorders are clinically and genetically heterogeneous with more than 150 gene
defects accounting for the diversity of disease phenotypes. So far, mutation detection was mainly performed by
APEX technology and direct Sanger sequencing of known genes. However, these methods are time consuming,
expensive and unable to provide a result if the patient carries a new gene mutation. In addition, multiplicity of
phenotypes associated with the same gene defect may be overlooked.
Methods: To overcome these challenges, we designed an exon sequencing array to target 254 known and
candidate genes using Agilent capture. Subsequently, 20 DNA samples from 17 different families, including four
patients with known mutations were sequenced using Illumina Genome Analyzer IIx next-generation-sequencing
(NGS) platform. Different filtering approaches were applied to identify the genetic defect. The most likely disease
causing variants were analyzed by Sanger sequencing. Co-segregation and sequencing analysis of control samples
validated the pathogenicity of the observed variants.
Results: The phenotype of the patients included retinitis pigmentosa, congenital stationary night blindness, Best
disease, early-onset cone dystrophy and Stargardt disease. In three of four control samples with known genotypes
NGS detected the expected mutations. Three known and five novel mutations were identified in NR2E3, PRPF3, EYS,
PRPF8, CRB1, TRPM1 and CACNA1F. One of the control samples with a known genotype belongs to a family with
two clinical phenotypes (Best and CSNB), where a novel mutation was identified for CSNB. In six families the
disease associated mutations were not found, indicating that novel gene defects remain to be identified.
Conclusions: In summary, this unbiased and time-efficient NGS approach allowed mutation detection in 75% of
control cases and in 57% of test cases. Furthermore, it has the possibility of associating known gene defects with
novel phenotypes and mode of inheritance.
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Background
Inherited retinal disorders affect approximately 1 in 2000
individuals worldwide [1]. Symptoms and associated phe-
notypes are variable. In some groups the disease can be
mild and stationary such as in congenital stationary night
blindness (CSNB) or achromatopsia (ACHM), whereas
other disorders are progressive leading to severe visual
impairment such as in rod-cone dystrophies, also known as
retinitis pigmentosa (RP) or cone and cone-rod dystro-
phies. The heterogeneity of these diseases is reflected in the
number of underlying gene defects. To date more than 150
genes have been implicated in different forms of retinal dis-
orders http://www.sph.uth.tmc.edu/Retnet/home.htm and
yet in a significant proportion of patients the disease caus-
ing mutation could not be identified, suggesting additional
novel genes that remain to be discovered. Furthermore,
recent studies have outlined that distinct phenotypes can
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be related to the dysfunction of the same gene [2-4].
Furthermore, there may be additional phenotype-genotype
associations that are still not recognized. The state-of-the-
art phenotypic characterization including precise family
history and functional as well as structural assessment (i.e.
routine ophthalmic examination, perimetry, color vision,
full field and multifocal electroretinography (ERG), fundus
autofluorescence (FAF) imaging and optical coherence
tomography (OCT)) allows targeted mutation analysis for
some disorders. However, in most cases of inherited retinal
diseases, similar phenotypic features can be due to a large
number of different gene defects.
Various methods can be used for the identification of
the corresponding genetic defect. All these methods have
advantages and disadvantages. Sanger sequencing is still
the gold-standard in determining the gene defect, but due
to the heterogeneity of the disorders it is time consuming
and expensive to screen all known genes. Mutation detec-
tion by commercially available APEX genotyping microar-
rays (ASPER Ophthalmics, Estonia) [5,6] allows the
detection of only known mutations. In addition, a separate
microarray has been designed for each inheritance pattern,
which tends to escalate the costs especially in simplex
cases, for which inheritance pattern cannot be predeter-
mined. Indirect methods with single nucleotide poly-
morphism (SNP) microarrays for linkage and
homozygosity mapping are also powerful tools, which has
proven its reliability in identifying novel and known gene
defects [7-12]. However, in case of homozygosity mapping
the method can only be applied to consanguineous
families or inbred populations. To overcome these chal-
lenges, we designed a custom sequencing array in colla-
boration with a company (IntegraGen, Evry, France) to
target all exons and part of flanking sequences for 254
known and candidate retinal genes. This array was subse-
quently applied through NGS to a cohort of 20 patients
from 17 families with different inheritance pattern and
clinical diagnosis including RP, CSNB, Best disease, early-
onset cone dystrophy and Stargardt disease.
Methods
Clinical investigation
The study protocol adhered to the tenets of the Declara-
tion of Helsinki and was approved by the local Ethics
Committee (CPP, Ile de France V). Informed written
consent was obtained from each study participant. Index
patients underwent full ophthalmic examination as
described before [13]. Whenever available, blood sam-
ples from affected and unaffected family members were
collected for co-segregation analysis.
Previous molecular genetic analysis
Total genomic DNA was extracted from peripheral blood
leucocytes according to manufacturer’s recommendations
(Qiagen, Courtaboeuf, France). DNA samples from some
patients with a diagnosis of RP were first analyzed and
excluded for known mutations by applying commercially
available microarray analysis (arRP and adRP ASPER
Ophthalmics, Tartu, Estonia). In some cases, pathogenic
variants in EYS, C2orf71, RHO, PRPF31, PRPH2 and RP1
were excluded by direct Sanger sequencing of the coding
exonic and flanking intronic regions of the respective
genes [13-17]. Conditions used to amplify PRPH2 can be
provided on request.
Molecular genetic analysis using NGS
A custom-made SureSelect oligonucleotide probe library
was designed to capture the exons of 254 genes for dif-
ferent retinal disorders and candidate genes according
to Agilent’s recommendations (Table 1). These genes
include 177 known genes underlying retinal dysfunction
(http://www.sph.uth.tmc.edu/retnet/sum-dis.htm, Octo-
ber 2010, Table 1) and 77 candidate genes associated
with existing animal models and expression data (Table
2). The eArray web-based probe design tool was used
for this purpose https://earray.chem.agilent.com/earray.
The following parameters were chosen for probe design:
120 bp length, 3× probe-tiling frequency, 20 bp overlap
in restricted regions, which were identified by the imple-
mentation of eArray’s RepeatMasker program. A total of
27,430 probes, covering 1177 Mb, were designed and
synthesized by Agilent Technologies (Santa Clara, CA,
USA). Sequence capture, enrichment, and elution were
performed according to the manufacturer’s instructions
(SureSelect, Agilent). Briefly, three μg of each genomic
DNA were fragmented by sonication and purified to
yield fragments of 150-200 bps. Paired-end adaptor oli-
gonucleotides from Illumina were ligated on repaired
DNA fragments, which were then purified and enriched
by six PCR cycles. 500 ng of the purified libraries were
hybridized to the SureSelect oligo probe capture library
for 24 h. After hybridization, washing, and elution, the
eluted fraction underwent 14 cycles of PCR-amplifica-
tion. This was followed by purification and quantifica-
tion by qPCR to obtain sufficient DNA template for
downstream applications. Each eluted-enriched DNA
sample was then sequenced on an Illumina GAIIx as
paired-end 75 bp reads. Image analysis and base calling
was performed using Illumina Real Time Analysis
(RTA) Pipeline version 1.10 with default parameters.
Sequence reads were aligned to the reference human
genome (UCSC hg19) using commercially available soft-
ware (CASAVA1.7, Illumina) and the ELANDv2 align-
ment algorithm. Sequence variation annotation was
performed using the IntegraGen in-house pipeline,
which consisted of gene annotation (RefSeq), detection
of known polymorphisms (dbSNP 131, 1000 Genome)
followed by mutation characterization (exonic, intronic,
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Table 1 Known retinal disease genes
Number Gene name
1 ABCA4
2 ABCC6
3 ADAM9
4 AHI1
5 AIPL1
6 ALMS1
7 ARL6
8 ARMS2
9 ATXN7
10 BBS10
11 BBS12
12 BBS2
13 BBS4
14 BBS5
15 BBS7
16 BBS9
17 BEST1
18 C1QTNF5
19 C2
20 C2orf71
21 C3
22 CA4
23 CABP4
24 CACNA1F
25 CACNA2D4
26 CC2D2A
27 CDH23
28 CDH3
29 CEP290
30 CERKL
31 CFB
32 CFH
33 CHM
34 CLN3
35 CLRN1
36 CNGA1
37 CNGA3
38 CNGB1
39 CNGB3
40 CNNM4
41 COL11A1
42 COL2A1
43 COL9A1
44 CRB1
45 CRX
46 CYP4V2
47 DFNB31
Table 1 Known retinal disease genes (Continued)
48 DMD
49 DPP3
50 EFEMP1
51 ELOVL4
52 ERCC6
53 EYS
54 FAM161A
55 FBLN5
56 FSCN2
57 FZD4
58 GNAT1
59 GNAT2
60 GPR98
61 GRK1
62 GRM6
63 GUCA1A
64 GUCA1B
65 GUCY2D
66 HMCN1
67 HTRA1
68 IDH3B
69 IMPDH1
70 IMPG2
71 INPP5E
72 INVS
73 IQCB1
74 JAG1
75 KCNJ13
76 KCNV2
77 KLHL7
78 LCA5
79 LRAT
80 LRP5
81 MERTK
82 MFRP
83 MKKS
84 MKS1
85 MTND1
86 MTND6
87 MT-AP6
88 MTND2
89 MTND5
90 MTND4
91 MYO7A
92 NDP
93 NPHP1
94 NPHP3
95 NPHP4
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silent, nonsense etc.). For each position, the exomic fre-
quencies (homozygous and heterozygous) were deter-
mined from all the exomes already sequenced by
IntegraGen and the exome results provided by HapMap
project.
Investigation of annotated sequencing data
We received the annotated sequencing data in the form
of excel tables. On average 946 SNPs and 83 insertions
and deletions were identified for each sample (Figure 1).
By using the filtering system, we first investigated var-
iants (nonsense and missense mutations, intronic
Table 1 Known retinal disease genes (Continued)
96 NR2E3
97 NRL
98 NYX
99 OAT
100 OFD1
101 OPA1
102 OPA3
103 OPN1LW
104 OPN1MW
105 OPN1Sw
106 OTX2
107 PANK2
108 PAX2
109 PCDH15
110 PCDH21
111 PDE6A
112 PDE6B
113 PDE6C
114 PDE6G
115 PDZD7
116 PEX1
117 PEX2
118 PEX7
119 PGK1
120 PHYH
121 PITPNM3
122 PRCD
123 PROM1
124 PRPF3
125 PRPF31
126 PRPF8
127 PRPH2
128 RAX2
129 RB1
130 RBP3
131 RBP4
132 RD3
133 RDH12
134 RDH5
135 RGR
136 RGS9
137 RGS9BP
138 RHO
139 RIMS1
140 RLBP1
141 ROM1
142 RP1
Table 1 Known retinal disease genes (Continued)
143 RP1L1
144 RP2
145 RP9
146 RPE65
147 RPGR
148 RPGRIP1
149 RPGRIP1L
150 RS1
151 SAG
152 SDCCAG8
153 SEMA4A
154 SLC24A1
155 SNRNP200
156 SPATA7
157 TEAD1
158 TIMM8A
159 TIMP3
160 TLR3
161 TLR4
162 TMEM126A
163 TOPORS
164 TREX1
165 TRIM32
166 TRPM1
167 TSPAN12
168 TTC8
169 TTPA
170 TULP1
171 UNC119
172 USH1C
173 USH1G
174 USH2A
175 VCAN
176 WFS1
177 ZNF513
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Table 2 Candidate genes for retinal disorders
Number Gene name Reason References
1 ADCY1 diff. Expression rd1 mouse Chalmel et al., manuscript in preparatiom
2 ANKRD33 diff. Expression rd1 mouse Chalmel et al., manuscript in preparatiom
3 ANXA2 Promotion of choroidal neovascularization [36]
4 ARL13B Cilia protein, mutations lead to Joubert Syndrome [37]
5 BMP7 Regulation of Pax 2 in mouse retina [38]
6 BSG - Thierry Leveillard personal commmunication
7 CAMK2D diff. Expression rd1 mouse Chalmel et al., manuscript in preparatiom
8 CCDC28B Modifier for BBS [39,40]
9 CLCN7 Cln7-/- mice severe osteopetrosis and retinal degeneration [41]
10 COL4A3 Alport syndrome, with eye abnormalities [42,43]
11 COL4A4 Alport syndrome, with eye abnormalities [42,44]
12 COL4A5 Alport syndrome, with eye abnormalities [42,45]
13 CUBN - Personal communication Renata Kozyraki
14 CYP1B1 glaucoma [46]
15 DOHH diff. Expression rd1 mouse Chalmel et al., manuscript in preparatiom
16 DSCAML1 diff. Expression rd1 mouse Chalmel et al., manuscript in preparatiom
17 ESRRB diff. Expression rd1 mouse Chalmel et al., manuscript in preparatiom
18 FIZ1 Interactor of NRL [47]
19 GJA9 diff. Expression rd1 mouse Chalmel et al., manuscript in preparatiom
20 GNAZ diff. Expression rd1 mouse Chalmel et al., manuscript in preparatiom
21 GNGT1 diff. Expression rd1 mouse Chalmel et al., manuscript in preparatiom
22 GPR152 diff. Expression rd1 mouse Chalmel et al., manuscript in preparatiom
23 HCN1 diff. Expression rd1 mouse Chalmel et al., manuscript in preparatiom
24 HEATR5A diff. Expression rd1 mouse Chalmel et al., manuscript in preparatiom
25 HIST1H1C Expressed in retina Expression databases
26 IMPG1 diff. Expression rd1 mouse Chalmel et al., manuscript in preparatiom
27 INSL5 diff. Expression rd1 mouse Chalmel et al., manuscript in preparatiom
28 KCNB1 diff. expression rd1 mouse Chalmel et al., manuscript in preparatiom
29 KCTD7 Expressed in retina Expression databases
30 LASS4 diff. expression rd1 mouse Chalmel et al., manuscript in preparatiom
31 LRIT2 diff. expression rd1 mouse Chalmel et al., manuscript in preparatiom Rd1 mouse
32 LRP2 - Personal communication Renata Kozyraki
33 MAB21L1 diff. expression Rd1 mouse Chalmel et al., manuscript in preparatiom
34 MAP2 diff. expression rd1 mouse Chalmel et al., manuscript in preparatiom
35 MAS1 Degeneration of cones due to expression of Mas1 [48]
36 MAST2 diff. expression rd1 mouse Chalmel et al., manuscript in preparatiom
37 MPP4 diff. expression rd1 mouse Chalmel et al., manuscript in preparatiom
38 MYOC glaucoma [49]
39 NDUFA12 diff. expression rd1 mouse Chalmel et al., manuscript in preparatiom
40 NEUROD1 BETA2/NeuroD1 -/- mouse: photoreceptor degeneration [50]
41 NOS2 glaucoma [51]
42 NXNL1 Rod-derived cone viability factor [52]
43 NXNL2 Rod-derived cone viability factor 2 [53]
44 OPN1MW2 Cone opsin, medium-wave-sensitive2 [54]
45 OPTN glaucoma [55]
46 PFKFB2 diff. expression rd1 mouse Chalmel et al., manuscript in preparatiom
47 PIAS3 Rod photoreceptor development [56]
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variants located +/- 5 apart from exon), which were
absent in dbSNP and NCBI databases http://ncbi.nlm.
nih.gov/. In the absence of known gene defects or puta-
tive pathogenic variants (see below) in the first step, we
selected known genes, which were previously clinically
associated including variants present in dbSNP and
NCBI databases (Figure 1). Each predicted pathogenic
variant was confirmed by Sanger sequencing.
Assessment of the pathogenicity of variants
Following criteria were applied to evaluate the patho-
genic nature of novel variations identified by NGS: 1)
stop/frameshift variants were considered as most likely
to be disease causing; 2) co-segregation in the family; 3)
absence in control samples; 4) for missense mutations
amino acid conservation was studied in the UCSC Gen-
ome Browser http://genome.ucsc.edu/ across species
from all different evolutionary branches. If the amino
acid residue did not change it was considered as “highly
conserved”. If a different change was seen in fewer than
five species and not in the primates then it was consid-
ered as “moderately conserved” and if a change was pre-
sent in 5-7, it was considered as “weakly conserved”,
otherwise the amino acid residue was considered as “not
conserved”, 5) pathogenicity predictions with bioinfor-
matic tools (Polyphen: Polymorphism Phenotyping,
http://genetics.bwh.harvard.edu/pph/ and SIFT: Sorting
Intolerant From Tolerant, http://blocks.fhcrc.org/sift/
SIFT.html) if at least one of the program predicted the
variant to be possibly damaging, it was considered to be
pathogenic; 6) presence of the second mutant allele in
the case of autosomal recessive inheritance. Mutations
were described according to the HGVS website http://
www.hgvs.org/mutnomen. In accordance with this
nomenclature, nucleotide numbering reflects cDNA
numbering with +1 corresponding to the A of the ATG
Table 2 Candidate genes for retinal disorders (Continued)
48 PKD2L1 Diff. expression in human retinal detachment Delyfer et al. 2011 submitted
49 PLEKHA1 Age-related macular degeneratiom [57]
50 PPEF2 diff. expression rd1 mouse Chalmel et al., manuscript in preparatiom
51 RAB8A Interacts with RPGR, role in cilia biogenesis and maintenance [58]
52 RABGEF1 diff. expression rd1 mouse Chalmel et al., manuscript in preparatiom
53 RCVRN diff. expression rd1 mouse Chalmel et al., manuscript in preparatiom
54 RGS20 diff. expression rd1 mouse Chalmel et al., manuscript in preparatiom
55 RNF144B diff. expression rd1 mouse Chalmel et al., manuscript in preparatiom
56 RORB Rod photoreceptor development in mice [59]
57 RXRG Retinoic acid receptor, highly expressed in the eye Expression databases
58 SGIP1 diff. expression rd1 mouse Chalmel et al., manuscript in preparatiom
59 SLC16A8 Altered visual function in ko-mice [60]
60 SLC17A7 diff. expression rd1 mouse Chalmel et al., manuscript in preparatiom
61 STAM2 diff. expression rd1 mouse Chalmel et al., manuscript in preparatiom
62 STK35 diff. expression rd1 mouse Chalmel et al., manuscript in preparatiom
63 STX3 diff. expression rd1 mouse Chalmel et al., manuscript in preparatiom
64 SV2B diff. expression rd1 mouse Chalmel et al., manuscript in preparatiom
65 TBC1D24 diff. expression rd1 mouse Chalmel et al., manuscript in preparatiom
66 THRB Essential for M-cone development in rodents [61]
67 TMEM216 Cilia protein, mutations lead to Joubert and Meckel syndrome [62]
68 TMEM67 Cilia protein, mutations lead to Joubert [63]
69 TRPC1 diff. expression rd1 mouse diff. expression Rd1 mouse
70 UHMK1 diff. expression rd1 mouse diff. expression Rd1 mouse
71 VSX1 Stimulator for promoter NXNL1 [64]
72 VSX2 Stimulator for promoter NXNL1 [64]
73 WDR17 diff. expression rd1 mouse diff. expression Rd1 mouse
74 WDR31 diff. expression Nxnl1-/- mouse [65]
75 WISP1 diff. expression rd1 mouse Chalmel et al., manuscript in preparatiom
76 XIAP Protects photoreceptors in animal models of RP [66]
77 ZDHHC2 diff. expression Rd1 mouse Chalmel et al., manuscript in preparatiom
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translation initiation codon in the reference sequence.
The initiation codon is codon 1. The correct nomencla-
ture for mutation was checked applying Mutalyzer
http://www.lovd.nl/mutalyzer/.
Results
The overall sequencing coverage of the captured regions
was 98.4% and 90.4% for a 1× and a 10× coverage respec-
tively. The overall sequencing depth was > 120×. The
number of reference and variant sequences detected by
NGS, reflected the correct zygosity state of the variant;
on average if 50% of the sequences represented the var-
iant, then a heterozygous state was called, while if 100%
of the sequences represented the variant, then a homozy-
gous or hemizygous state was annotated by IntegraGen.
Validation of the novel genetic testing tool for retinal
disorders
To validate the novel genetic testing tool for retinal dis-
orders, we used four DNA samples from families, in
which we had previously identified different types of
mutations by Sanger sequencing: one 1 bp duplication
and one 1 bp deletion in PRPF31 and missense muta-
tions in TRPM1 and BEST1 (Table 3). Three of the four
mutations were detectable by NGS, whereas the deletion
in PRPF31 was not identified. To validate if this was due
to a technical problem of deletion detection in general
or low coverage at this position, the sequencing depth
was investigated in detail. Indeed the coverage at this
position reflected by the mean depth was only ~1-6 for
all samples. This indicates that although the coverage in
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Figure 1 Flow chart of variant analysis. IntegraGen provided the results in form of excel tables. For each sample on average 946 SNPs and 83
inDels were detected, of which 11 represent missense, nonsense or putative splice site mutations, which were absent in dbSNB, NCBI and 1000
genome databases. Of those 1-5 variants were predicted to be pathogenic. In case where none of the variants were predicted to be pathogenic,
dbSNB, NCBI and 1000 genome databases were included to detect mutations referenced with an rs-number. Co-segregation analysis was
performed in families with putative pathogenic variants.
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general was very good, specific probes used here need to
be redesigned to improve the capture for specific exons.
Detection of known and novel mutations
Some of the patients from the 14 families with no
known gene defect were previously excluded for known
mutations using microarray analysis and by Sanger
sequencing in the known genes EYS, C2orf71, RHO,
PRPF31, PRPH2 and RP1. Other samples were never
genetically investigated. In four DNA samples known
mutations were detected (Table 4) from three different
families with autosomal dominant (ad) or recessive (ar)
RP. All mutations co-segregated with the phenotype
(Figure 2). In seven samples, novel mutations in known
genes were identified. These mutations co-segregated
with the phenotype from five different families with
adCSNB, x-linked incomplete CSNB, adRP, arRP and x-
linked RP (Table 5, Figures 3 and 4). One of the cases
from these five families was also used as a control for
Best disease carrying a known BEST1 mutation (Table
3). In addition to the Best phenotype, ERG-responses of
this patient resembled those of complete CSNB, i.e.
showing selective ON-bipolar pathway dysfunction. This
phenotype was independent of the Best phenotype (Fig-
ure 3). The most likely disease causing mutation
detected by NGS was a novel heterozygous TRPM1
mutation (Table 4, Figure 3).
Unsolved cases
In six of the 14 families with Stargardt disease, adRP,
adCD with postreceptoral defects, arRP, early onset
arCD with macrocephaly and mental retardation
described in affected sister and x-linked cCSNB, the dis-
ease associated mutations remain to be elucidated or
validated (Table 6, Figure 5).
Discussion
By using NGS in 254 known and candidate genes we
were able to detect known and novel mutations in 57%
of families tested. In order to achieve this goal, we
applied a rigorous protocol (Figure 1). To our knowl-
edge, this is the first report using NGS to investigate all
inherited retinal disorders at once. In a study restricted
to adRP, Bowne and co-workers used a similar approach
including 46 known and candidate genes for adRP [18].
All their cases had previously been screened and
excluded for most of the known genes underlying adRP.
The authors were able to identify known or novel muta-
tions in five out of 21 cases in genes not included in a
pre-screening [18]. This added five patients to their
Table 3 Patients with known mutations used to validate the novel genetic approach for retinal disorders
Index Phenotype Gene Mutation Allele
State
Read reference
NGS
Read variant
NGS
Mutation detected by
NGS
Mean
depth
CIC00034,
F28
adRP PRPF31 c.666dup
p.
I223YfsX56
het 11 13 yes 21.3-22.5
CIC00140,
F108
adRP PRPF31 c.997delG
p.
E333SfsX5
het - - no 5.0-5.2
CIC00238,
F165
arCSNB TRPM1 c.1418G >
C
p.R473P
homo 0 38 yes 36.7
CIC00707,
F470
Best and adCSNB see
Table 5
BEST1 c.73C > T
p.R25W
het 40 38 yes 99.4
Table 4 Detection of known mutations by using the novel genetic approach for retinal disorders
Index Phenotype Pre-screening Gene Mutation Allele
State
Read
reference
NGS
Read
variant
NGS
Reference Mutation verified by
Sanger and co-
segregation
CIC00019,
F16
adRP Linkage, RHO,
PRPF31, PRPH2,
RP1
PRPF3 c.1481C > T
p.T494M
het 25 22 [67] yes
CIC0000893,
F574
adRP RHO, PRPF31,
PRPH2, RP1
NR2E3 c.166G > A
p.G56R
het 5 3 [68] yes
CIC000128,
F100
arRP,
consang.
- EYS c.408_423del
p.N137VfsX24
homo - 179 [13,69] yes
CIC0000943,
F100
arRP,
consang
- EYS c.408_423del p.
N137VfsX24
homo 0 193 [13,69] yes
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adRP cohort with known gene defects, indicating that
64% of their patients show known mutations with new
genes still to be discovered in the remaining 36%. The
current study provides a more exhaustive tool, since it
incorporates screening of 254 genes implicated in var-
ious retinal disorders of different inheritance patterns
and additional candidate genes for these phenotypes.
With this approach a cohort of both pre-screened and
unscreened samples, was investigated. The mutation
detection rate of 57% is high and was never obtained
before by high throughput screening methods. Further-
more, this approach is probably less time consuming
and expensive than existing methods such as direct
sequencing of all known genes or microarray analysis.
Of note however is one of the variants detected with the
NGS approach (i.e. p.V973L exchange in GUCY2D),
which was not confirmed by direct Sanger sequencing,
suggesting the possibility of false positive using the high
throughput screening. Verification by direct Sanger
sequencing of most likely pathogenic variants is there-
fore essential to validate NGS data, although the false
positive rate is assumed to be low (in our study 1/28
verified sequence variants represented a false positive).
Overall, the study of 20 subjects from 17 families by
NGS showed that most of the targeted regions are well
covered (more than 98%). However, some of the regions
showed a lower coverage (GC-rich regions) or were not
captured (repetitive regions). This was for instance the
case for two genes underlying cCSNB, (i.e. NYX and
GRM6) and the repetitive region of ORF15 of RPGR.
For GC-rich regions the capture design could be
improved in the future by modifying NGS chemistry, as
Fam 16: PRPF3: M: c.1481C>T p.T494M
? ?
352
19 3266
3113
909 984
3361
983 1259 1248 1119 1023 911 913 1167 1166 1036 1037 1143 1421
843 3239
1250 3455 1120 3240 910 1165 3263
932 982 1145 1069 3251
108437801073142311421035
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[M]+[=][M]+[=]
Fam 100: EYS: M: c.408_423del16 p.N137VfsX24
128
[M]+[M]
203
[M]+[M]
3744
[M]+[M]
181
[M]+[M]
943
[M]+[M]
[M]+[=]
Fam 574: NR2E3: M: c.166G>A p.G56R
[M]+
[=]
893 2501
[M]+
[=]
2761
[=]+
[=]
1394
[M]+
[=]
2733
[=]+
[=]
2502 1395894
[M]+
[=]
[M]+
[=]
[=]+
[=]
1808
[M]+[M]
Figure 2 Detection of known mutations by NGS in 254 retinal genes. The index patient 19 of family 16 with adRP revealed the p.T494M
mutations in PRPF3, which co-segregates with the phenotype. Two family members never clinically investigated from the last generation (984
and 1167 carrying a question mark) were reported to be not affected but carried the mutation. They may develop the phenotype at a later
stage. In addition variability of the phenotype of this mutation was documented [35]. Two patients, 128 and 943 of family 100 with arRP from
Jewish origin revealed the known EYS mutation p.N137VfsX24, which was found in all screened affected family members. The index patient 893
of family 574 showed the previously described NR2E3 p.G56R mutation, which co-segregated with the phenotype.
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it was successfully achieved for Sanger sequencing using
different additives, which improved the amplification
and subsequent sequencing. If repetitive regions like
ORF15 of RPGR remain problematic for sequencing by
NGS, direct Sanger sequencing of these targets might be
the first screening of choice; in particular for disorders
caused only by a few gene defects such as CSNB, and
xl-RP.
By applying NGS sequencing to our retinal panel,
known and novel mutations were detected in different
patients. We believe that our diagnostic tool is particu-
larly important for heterogeneous disorders like RP, for
which many gene defects with different prevalence have
been associated to one phenotype. It also allows the
rapid detection of novel mutations in minor genes
which are often not screened as a priority by direct San-
ger sequencing. This was the case in our study for three
individuals from one family with adRP in which NGS
detected a novel PRPF8 mutation in both affected and
one unaffected family member (Table 4, Figure 4). In
this family, the RP phenotype is mild and therefore it is
possible that the unaffected member may develop symp-
toms later in life or alternatively it may be a case of
incomplete penetrance as reported for another splicing
factor gene, PRPF31 and recently for PRPF8 as well
[19-22]. Interestingly, a novel TRPM1 mutation was
identified in a patient with adCSNB, a gene previously
only associated with arCSNB [23-26]. This is the first
report of a TRPM1 mutation co-segregating with ad
Schubert-Bornschein type complete CSNB. Since the
location of this mutation is not different compared to
other mutations leading to arCSNB, it is not quite clear
how TRPM1 mutations might lead to either ad or
arCSNB. Functional investigations are needed to validate
the pathogenicity of this variant. Furthermore, this find-
ing suggests that TRPM1 heterozygous mutation carriers
from arCSNB families should be investigated by electro-
retinography to determine whether they display similar
retinal dysfunction as in affected members of the pre-
sented adCSNB family. Detection of a novel RPGR splice
site mutation in family 146 presented a challenge. The
actual disease causing change was concealed under a
wrongly annotated rs62638633, which had previously
been clinically associated to RP by a German group
http://www.ncbi.nlm.nih.gov/sites/varvu?gen-
e=6103&rs=62638633, (personal communication, Mar-
kus Preising). These observations indicate that the
stringent filtering we applied initially can mask those
Table 5 Detection of novel mutations by using the novel genetic approach for retinal disorders
Index Phenotype Pre-
screening
Gene Mutation Allele
State
Read
reference
NGS
Read
variant
NGS
Mutation
verified by
Sanger and
co-
segregation
Conservation Polyphen Sift
CIC00707,
F470
adCSNB
and Best
see Table 3
RHO,
PDE6B,
GNAT1
TRPM1 c.1961A
> C
p.H654P
het 39 38 yes moderately
conserved
possibly
damaging
tolerated
CIC000348,
F232
adRP, mild RHO,
PRPF31,
PRPH2,
RP1, adRP
chip
PRPF8 c.6992A
> G
p.
E2331G
het 13 10 yes moderately
conserved
possibly
damaging
affect
protein
function
CIC000346,
F232
adRP - PRPF8 c.6992A
> G
p.E2331G
het 5 9 yes moderately
conserved
possibly
damaging
affect
protein
function
CIC000347,
F232
as
adRP
- PRPF8 c.6992A
> G
p.E2331G
het 15 17 yes moderately
conserved
possibly
damaging
affect
protein
function
CIC04240,
F2025
arRP,
consang.,
detailed
clinic in
[70]
RS1 CRB1 c.2219C
> T
p.S740F
homo 2 194 yes highly
conserved
probably
damaging
affect
protein
function
CIC00199,
F146
adRP or x-
linked RP
with
affected
carrier
RHO,
PRPF31,
PRPH2,
RP1, adRP
chip
RPGR c.248-2A
> G
splice
defect
hetero 30 22 yes conserved
splice site
n.a. n.a.
CIC04094,
F1915
icCSNB - CACNA1F c.973C >
T
p.Q325X
hemi 0 28 yes n.a. n.a. n.a.
Audo et al. Orphanet Journal of Rare Diseases 2012, 7:8
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referenced disease causing variants. Bearing this in mind
one can still first investigate unknown variants, but
should then examine dbSNP for referenced variants
either described to be disease causing, having a low
minor allele frequency or present in interesting candi-
date genes. An accurate discrimination of non-patho-
genic polymorphisms versus disease causing
polymorphism in SNP databases is warranted to resolve
this challenge.
In six families from the investigated cohort the disease
causing mutations still remain to be identified. In the
Stargardt patient with no pathogenic ABCA4 mutations
two variants in CFH were detected, one of which
(rs1061170) had previously been reported to predispose
to age related macular degeneration (AMD) [27-29]. The
second CFH change is a novel variant, affecting a highly
conserved residue, not found in NGS data from the other
19 samples and never associated with a disease. The
variants co-segregated in the only available family mem-
bers, which were the patient’s parents. Apart from the
association with AMD, CFH mutations have been pre-
viously associated with renal diseases, the most common
being membranoproliferative glomerulonephritis and
hemolytic uremic syndrome, which can be also associated
with an eye phenotype [30,31]. No renal dysfunction was
present in our patient. To validate if the two variants
identified in CFH are indeed disease causing, the DNA
samples from other available family members for co-seg-
regation analysis as well as characterization of functional
consequences of the novel variant are needed. One
patient with complete CSNB had an affected nephew and
thus x-linked inheritance was assumed. However, neither
Sanger nor NGS detected a mutation in the only known
x-linked gene, NYX, causing cCSNB. To exclude reces-
sive inheritance TRPM1 and GRM6 were investigated in
detail. Indeed the patient carried a novel heterozygous
Fam 470: BEST1: M1: c.73C>T p.R25W;  TRPM1: M2:c.1961A>C p.H654P 
 
707 
[M1]+[=] 
705 
[M1]+[=] 
706 
[M1]+[=] 
2715 
[=]+[=] 
708 
[=]+[=] 
Best disease 
 
cCSNB  
 
707 
[M2]+[=] 
705 
[M2]+[=] 
706 
[=]+[=] 
2715 
[M2]+[=] 
708 
[M2]+[=] 
OD 
OS 
Arden ratio 
Arden ratio 
a b 
c d e 
Figure 3 Best disease and CSNB co-segregating in one family. a) Sanger and NGS detected in all patients with Best disease a BEST1
mutation. b) NGS detected in all patients with a cCSNB phenotype a novel TRPM1 mutation. c) Fundus colour photographs (above) and fundus
autofluorescence (below) of patient 707 showing multiple yellow deposits within the posterior pole which are hyper autofluorescent d) Electro-
oculogram of patient 707 showing no slight rise after illumination in keeping with the diagnosis of Best disease e) Full Field Electroretinogram of
patient 707 showing ON-bipolar cell pathway dysfunction in keeping with the diagnosis of cCSNB.
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TRPM1 variant, which affects a highly conserved amino
acid and was not identified in the other 19 samples inves-
tigated here (Table 6). However, direct Sanger sequen-
cing of lower covered regions did not identify a second
mutation in this gene. Similarly no mutations in GRM6
were identified. These findings outline the need for addi-
tional family members to determine, through co-segrega-
tion, the pathogenicity of the numerous variants
identified by NGS. This was also true for two other
families with nonsense mutations in CUBN (Fam795)
and RP1L1 (Fam761) (Table 6). The nonsense mutation
in CUBN, co-segregated with the phenotype in most of
the family members (Figure 5). Had we not had access to
additional family members, we might have retained this
gene defect as the underlying cause for adCD and consid-
ered CUBN as a new gene involved in adCD. None of the
other putatively pathogenic mutations identified in
CUBN, TRPM1 and GUCY2D co-segregated with the
phenotype in this family (Table 6, Figure 5). RP1L1 was
already a candidate for adRP [32] but was previously
associated with occult macular dystrophy [33]. In our
study, this variant did not co-segregate with the pheno-
type in other affected family members (data not shown).
This NGS study ended with six genetically unresolved
families, which can be further investigated with whole
exome sequencing. Although, no clear information
about the actual percentage of missing gene defects
underlying each group of inherited retinal disorders
exists, previous studies have reported that in many cases
the genetic cause still needs to be determined [18,34].
Whole exome sequencing approaches allow the detec-
tion of both, novel and known gene defects, but also
generate numerous variants and therefore require the
inclusion of more than one DNA sample for each family
to rapidly exclude non-pathogenic variants. Due to the
higher costs of exome sequencing for one sample com-
pared to targeted sequencing, we propose to initially
perform targeted sequencing in the index patient and
proceed only after exclusion of a known gene defect to
whole exome sequencing.
Fam 2025: CRB1: M: c.2219C>T p.S2740F
Fam 146: RPGR: M: c.248-2A splice defect
Fam 1915: CACNA1F: M: c.973C>T p.Q325X
?
346
[M]+[=]
348
[M]+[=]
347
[M]+[=]
4241
[M]+[M]
4240
[M]+[M]
4499
[M]+[=]
4242
[M]+[=]
4094
[M]
4248
[M]+[=]
Fam 232: PRPF8: M: c.6992A>G p.E2331G
[M]+[=]
219
[M]+[=]
200
[M]+[=]
220
[M]+[=]
199
?
[M]+[=]
222
[M]
221
Figure 4 Detection of novel mutations using NGS in 254 retinal genes. Novel mutations in PRPF8, CRB1, RPGR and CACNA1F co-segregated
in affected and asymptomatic carriers with the adRP, arRP, x-linked dominant and X-liked icCSNB phenotypes respectively. Asymptomatic
individuals are marked with a question mark.
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Table 6 Patients with unsolved genotype and unlikely disease causing mutations
Index Phenotype Pre-
screening
Gene Mutation Allele
State
Read
reference
NGS
Read
variant
NGS
Mutation verified by
Sanger and co-
segregation
Comment
CIC03282,
F1388
Stargardt ABCA4
microarray
ABCA4 c.1268A > G
p.H423R
het 77 61 yes but reported as
polymorphism
[71]
c.6764G > T
p.S2255I
no
additional
variants in
lower
covered
exons
het 2 7 yes but reported
as polymorphism
[72]
CFH c.3482C > A
p.P1161Q
het 77 52 yes conserved,
probably
damaging
c.1204C > T
p.H402Y
het 94 87 yes AMD
CIC01269,
F761
adRP - RP1L1 c.5959C > T
p.Q1987X
het 145 150 yes, did not co-segregate pass to whole
exome
sequencing
CIC01312,
F795
adCD with post-
receptoral defects
RHO,
PDE6B,
GNAT1
adRP chip
CUBN c.127C > T
p.R43X
het 139 102 yes, did not co-segregate pass to whole
exome
sequencing
CUBN c.9340G > A
p.G3114S
het 61 44 yes, did not co-segregate
GUCY2D c.1499C > T
p.P500L
het 41 34 yes, did not co-segregate
TRPM1 c.3904T > C
p.C1302R
het 102 99 yes, did not co-segregate
CIC03225,
F1362
arRP consang. arRP chip PROM1 c.314A > G
p.Y105C
het 120 115 yes, but no additional
mutation
no homo, no
compound hets,
pass to whole
exome
sequencing
GUCY2D c.2917G > A
p.V973L
het 6 2 false positive, not found
by Sanger
DSCAML1 c.592C > T
p.R198C
het 70 81 yes, but no additional
mutation
TBC1D24 c.641G > A
p.R214H
het 27 12 yes, but no additional
mutation
TMEM67 c.1700A > G
p.Y567C
het 80 58 yes, but no additional
mutation
CIC04757
F2364
Index and affected
sister early onset
arCD, macro-
cephaly and
mental retardation
in affected sister
consang.
- IMPG2 c.3439C > T
p.P1147S
homo 0 140 no Polyphen and Sift
benign, not
conserved
PKD2L1 c.1027C > T
p.R343C
het 63 68
c.1202T > G
p.V401G
het 25 19 appeared also
het in 11 of our
samples
appeared also
het in affected
sister but no
other mutation in
less covered
exons
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Conclusions
In summary, our diagnostic tool is an unbiased time
efficient method, which not only allows detecting known
and novel mutations in known genes but also potentially
associates known gene defects with novel phenotypes.
This genetic testing tool can now be applied to large
cohorts of inherited retinal disorders and should rapidly
deliver the prevalence of known genes and the percen-
tage of cases with missing genetic defect for underlying
forms of retinal disorders.
List of abbreviations
ad: autosomal dominant; ar: autosomal recessive; as: asymptomatic; het:
heterozygous; homo: homozygous; hemi: hemizygous; - not noted; consang.:
Table 6 Patients with unsolved genotype and unlikely disease causing mutations (Continued)
DFNB31 c.1943C > A
p.S648Y
het 7 7 yes affected sister
also both variants
but both come
from father, no
other variant in
lower covered
region.
c.2644C > A
p.R882S
het 27 14 yes
EYS c.7597A > G
p.K2533E
het 151 149 yes Affected sister
does not carry
this variant
RPGRIP1 c.2417C > T
p.T806I
het 138 132 no not conserved
CIC04152,
F1955
male x-linked
cCSNB, has
affected nephew
NYX TRPM1 c.470C > T
p.S157F
het 118 130 yes, no other het
mutation.
x-linked
inheritance and
phenotype
verification
Index patients and respective gene defect are highlighted in bold. In some cases also family members were used for NGS.
Fam 795:  
M1: CUBN: c.127C>T p.R43X 
M2: CUBN: c.9340G>A p.G311S 
M3: GUCY2D: c.1499C>T p.P500L 
M4: TRPM1: c.3904T>C p.C1302R 
? 
1396 1402 
+ 
+ + + + 
? 
2771 2819 
? 
2911 1371 1312 
1369 1370 
* * * 
2566 
3013 
? ? 
[=]+[=] 
[M3]+[=] 
[=]+[=] [M3]+[=] [=]+[=] 
[=]+[=] 
* 
[=]+[=] [M4]+[=] [M4]+[=] [M4]+[=] 
[M4]+[=] [M4]+[=] 
[M1]+[M2] [M1]+[M2] 
[=]+[=] [M1]+[M2] [M1]+[M2] [=]+[=] 
5008 
4921 
[=]+[=] 
[M4]+[=] 
[M1]+[M2] 
[=]+[=] 
[=]+[=] 
[=]+[=] 
[=]+[=] 
[=]+[=] 
[=]+[=] 
? 
[=]+[=] 
[=]+[=] 
[=]+[=] 
[=]+[=] 
[=]+[=] 
[=]+[=] 
[=]+[=] 
[=]+[=] 
[=]+[=] 
[=]+[=] 
[=]+[=] 
[=]+[=] 
Figure 5 Detection of novel mutation by using NGS in 254 retinal genes. Family 795 reveals autosomal dominant cone dystrophy with
post-receptoral defects. Four putative disease causing mutations were investigated on the basis of co-segregation. However, none of them co-
segregated in all affected family members with the phenotype and thus are not considered to be disease causing. Individuals marked with a star
were clinically investigated, patients with a question mark are asymptomatic and patients with a plus sign show high myopia.
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consanguinity was reported; n.a.: not applicable; CSNB: congenital stationary
night blindness; RP: retinitis pigmentosa:
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